Voyager Therapeutics is a gene therapy company developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s pipeline is focused on severe neurological diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia and Alzheimer’s disease and severe chronic pain.
Voyager has an exciting semester long, full-time Co-op opportunity. The selected candidate will work on addressing this future concern by developing high productivity processes. The goals of this project is to identify and study the impact of Sf9 specific, production boosting additives on AAV productivity and quality; optimization of an AAV production process to meet pre-clinical and clinical product demand.
The individual will gain a deep understanding about upstream process development. He/She will learn new and developing technologies in the gene therapy space, such as perfusion and gene vector production using baculovirus system. They will also learn how upstream process development collaborates with other functional groups to contribute towards CMC development of gene therapy pipeline
Evaluation and Project Completion:
Project’s progress and the intern’s development will be evaluated regularly through frequent meetings with supervisor and presentations during internal group meetings
On project completion, the selected intern would be expected to present his/her work and findings to a larger internal audience via a poster or oral presentation.